Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29363077 | 0.81 | ATM (1.00) | ATMCYP3A4TAS2R46RECQLPTGS2 | |
| SCHEMBL29494186 | 0.81 | ATM (1.00) | ATMCYP3A4TAS2R46RECQLPTGS2 | |
| SCHEMBL4062532 | 0.63 | RECQL (0.37) | ATMCYP3A4TAS2R46RECQLKEAP1 | |
| SCHEMBL10577670 | 0.60 | CYP3A4 (0.52) | CYP3A4RECQLCYP19A1MAPTTP53 | |
| SCHEMBL29625296 | 0.59 | ATM (0.55) | ATMCYP3A4TAS2R46RECQLCYP19A1 | |
| SCHEMBL31058464 | 0.58 | ATM (0.51) | ATMCYP3A4TAS2R46RECQLCYP19A1 | |
| SCHEMBL11046051 | 0.58 | IDO1 (0.35) | CYP3A4RECQLPTGS2CYP19A1 | |
| SCHEMBL10061295 | 0.58 | PAX8 (0.36) | CYP3A4PTGS2MAPTTP53 | |
| SCHEMBL10307313 | 0.57 | TAS2R46 (0.61) | CYP3A4TAS2R46RECQLCYP19A1 | |
| SCHEMBL4998367 | 0.57 | RECQL (0.48) | ATMCYP3A4RECQLCYP19A1ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389744-B1 | DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2025-12-03 | — | — | EP | claimed |
| EP-3994138-B1 | ESTROGEN-RELATED RECEPTOR ALPHA (ERRALPHA) MODULATORS | LEAD PHARMA HOLDING BV (NL) | 2025-04-02 | — | — | EP | claimed |
| EP-4041733-B1 | DERIVATIVES HAVING 2,3-DIHYDRO-1H-INDENE OR 2,3-DIHYDROBENZOFURAN MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2024-05-08 | — | — | EP | claimed |
| EP-4041734-B1 | DERIVATIVES HAVING 1,2,3,4-TETRAHYDRONAPHTHALENE MOIETY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2024-04-24 | — | — | EP | claimed |
| EP-4341007-A1 | METHODS OF COATING SUBSTRATES AND COATED SUBSTRATES | Swimc LLC (US) | 2024-03-27 | — | — | EP | claimed |
| EP-3632911-B1 | METHOD FOR PREPARING ISOXAZINONE COMPOUND AND APPLICATION THEREOF | ZHEJIANG ZHUJI UNITED CHEMICALS CO LTD (CN) | 2023-08-09 | — | — | EP | claimed |
| WO-2022246127-A1 | METHODS OF COATING SUBSTRATES AND COATED SUBSTRATES | SWIMC LLC (US) | 2022-11-24 | — | — | WO | claimed |
| EP-4640768-A1 | CELLULOSE FIBER-CONTAINING MOLDED ARTICLE, AND METHOD FOR MANUFACTURING SAME | Oji Holdings Corporation (JP) | 2025-10-29 | — | — | EP | disclosed |
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) | 2025-08-14 | — | — | US | disclosed |
| US-20250136822-A1 | METAL PACKAGING POWDER COATING COMPOSITIONS, COATED METAL SUBSTRATES, AND METHODS | SWIMC LLC (US) | 2025-05-01 | — | — | US | disclosed |
| CN-119661711-A | CD8 binding agents and uses thereof | 豪夫迈·罗氏有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12173183-B2 | Metal packaging powder coating compositions, coated metal substrates, and methods | SWIMC LLC (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240385559-A1 | METHODS OF COATING SUBSTRATES AND COATED SUBSTRATES | SWIMC LLC (US) | 2024-11-21 | — | — | US | disclosed |
| WO-2022209940-A1 | PELLET | 住友化学株式会社 | 2022-10-06 | — | — | WO | disclosed |
| CN-111315821-B | Liquid crystal polyester resin composition and molded article | 住友化学株式会社 | 2022-09-23 | — | — | CN | disclosed |
| EP-4058210-A1 | METAL PACKAGING POWDER COATING COMPOSITIONS, COATED METAL SUBSTRATES, AND METHODS | Swimc LLC (US) | 2022-09-21 | — | — | EP | disclosed |
| WO-2022191099-A1 | LIQUID CRYSTAL RESIN COMPOSITION, AND MOLDED ARTICLE COMPRISING SAME | 東レ株式会社 | 2022-09-15 | — | — | WO | disclosed |
| US-20220266476-A1 | PELLET OF LIQUID CRYSTAL POLYESTER RESIN COMPOSITION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2022-08-25 | — | — | US | disclosed |
| US-20220228006-A1 | METAL PACKAGING POWDER COATING COMPOSITIONS, COATED METAL SUBSTRATES, AND METHODS | SWIMC LLC (US) | 2022-07-21 | — | — | US | disclosed |
| CN-114621884-A | Bacillus subtilis and application thereof in water purification | 山东蔚蓝生物科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255850-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATING NEUROLOGICAL CONDITIONS | NLN, ACHE, PYGB | ATM 3135/4885CYP3A4 2004/4885TAS2R46 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.